Revolution Medicines Announces Breakthrough in Pancreatic Cancer Treatment with Successful Phase III Trial of Daraxonrasib

　　【Pharmaceutical Network Industry Dynamics】 Pancreatic cancer is a highly aggressive disease. According to incomplete statistics, in 2022, the number of new cases of pancreatic cancer worldwide reached approximately 512,000, and it is expected to increase to 542,000 by 2024, further rising to 639,000 by 2030. In China, the incidence of pancreatic cancer has remained high, with an annual number of new cases reaching 119,000, accounting for about 22.8% of the global total.
 

As the number of patients continues to grow, the market size of this drug is also expanding. Data shows that the global pancreatic cancer drug market size was approximately USD 20 billion in 2018 and is expected to increase to USD 34 billion by 2025. Among this, China's pancreatic cancer drug market size has grown from CNY 1.3 billion in 2018 to CNY 1.9 billion in 2023, with a compound annual growth rate (CAGR) of 7.9%, and it is projected to reach CNY 2.7 billion by 2025.
 

In response to the growing patient demand and vast market potential, numerous pharmaceutical companies both in China and abroad are accelerating their expansion into this field. It is reported that since 2026, there have been significant breakthroughs in new drug development. For instance, on April 13, Revolution announced positive results from the phase III clinical trial RASolute 302 of pan-RAS inhibitor Daraxonrasib for previously treated metastatic pancreatic cancer patients, with survival benefits nearly doubling compared to standard chemotherapy.
 

According to reports, as a pan-RAS inhibitor entering Phase III, Daraxonrasib can directly bind to all RAS protein subtypes in the activated (ON) state, blocking downstream signaling pathways, covering more than 90% of pancreatic cancer patients. In the intent-to-treat population, the median OS for this drug was 13.2 months, compared to 6.7 months for chemotherapy (HR 0.40, p<0.0001). The nearly doubled OS data demonstrates its potential dominance.
 

Based on the excellent results of this study, the company expects to submit its marketing application as soon as possible. Considering that RMC6236 has already received FDA Breakthrough Therapy Designation and "Accelerated Review" status, its market entry process is expected to speed up.
 

On March 24, Qilu Pharmaceutical announced that its self-developed Claudin18.2/CD3 bispecific antibody QLS31905 had been granted Orphan Drug Designation (ODD) by the U.S. FDA, with the designated indication being pancreatic cancer. As a bispecific antibody drug, QLS31905 works by simultaneously binding to Claudin18.2 on the surface of tumor cells and CD3 on the surface of T cells, precisely recruiting and activating the body's own immune cells to achieve targeted killing of tumor cells.
 

Previously, the preliminary and updated results of the Phase I clinical study of QLS31905 showed that the drug has good safety and tolerability, and demonstrated positive efficacy signals in patients with Claudin18.2-positive advanced gastrointestinal tumors. Additionally, the potential breakthrough clinical value of this drug in combination therapy holds promise to fill the immunotherapy gap for pancreatic cancer patients.
 

In February, Hengrui Medicine announced that its KRAS G12D inhibitor HRS-4642 combined with chemotherapy (gemcitabine + nab-paclitaxel) for the first-line treatment of advanced pancreatic cancer with KRAS G12D mutation was included in the breakthrough therapy category by the CDE.
 

HRS-4642 Injection is a KRAS G12D inhibitor independently developed by the company, in a liposome formulation. This product can specifically bind to KRAS G12D, inhibiting the phosphorylation of MEK and ERK proteins, thereby exerting an anti-tumor effect. Results from a Phase Ib/II clinical study presented at the 2025 ESMO Congress showed that HRS-4642 combined with chemotherapy demonstrated promising efficacy and safety in treating patients with advanced pancreatic cancer harboring KRAS G12D mutations.
 

　　……
 

Overall, since 2026, the field of pancreatic cancer drug development has witnessed several key breakthroughs, particularly achieving substantial progress in targeting the challenging KRAS G12D mutation. Industry experts predict this year will be a turning point for pancreatic cancer drug research, with pharmaceutical companies advancing on multiple fronts to bring more hope to the treatment of this disease.
 

　　Disclaimer: In no event shall the information or opinions expressed in this article constitute investment advice to any person.